Fredun Pharmaceuticals: Press Release issued by Fredun Pharmaceuticals Limited
Fredun Pharmaceuticals (FREDUN) filed a disclosure titled "Press Release issued by Fredun Pharmaceuticals Limited". The company is valued at about ₹2,551 crore.
What happened
Fredun Pharmaceuticals (FREDUN) filed a disclosure with the exchanges on 8 October 2026 at 09:33 AM titled "Press Release issued by Fredun Pharmaceuticals Limited".
Company snapshot
Fredun Pharmaceuticals is a small-cap company, with a market value of about ₹2,551 crore.
The stock last traded at ₹1,542.5, against a 52-week range of ₹1,195.2–₹1,590 (3.0% below the high).
Before this filing the shares had moved +4.9% over the month. Average daily turnover over the last 20 sessions was about ₹11.4 crore.
Promoters held 44.57% at the end of Q2 FY27. Foreign institutions owned 1.06% and domestic institutions 2.94%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 119 | 6.8 | 14.33 |
| Q2 FY26 | 144 | 9.7 | 20.61 |
| Q3 FY26 | 160 | 10.5 | 19.53 |
| Q4 FY26 | 210 | 11.1 | 20.22 |
| Q1 FY27 | 228 | 13.2 | 23.89 |
What history shows
BCEIE's records show 12 or more previous corporate update filings from the company since May 2026.
After those filings, the stock fell 3.3% on average the next trading day and was down 1.4% on average after five days (7 filings with price data).
Market-wide, 97 corporate update filings with an impact score of 50 or more saw an average next-day move of −1.1%, with 33% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 22 Sept 2026 | Press Release by FPL dated- 22-09-2026 | +3.4% | +3.3% |
| 16 Sept 2026 | Allotment of 2,71,200 Equity Shares to Non-Promoter upon conversion… | +6.7% | +11.4% |
| 15 Sept 2026 | Press Release | −13.5% | −2.1% |
| 15 Sept 2026 | PRESS RELEASE | −13.5% | −2.1% |
| 8 Sept 2026 | Press Release issued by Fredun Pharmaceuticals Limited | +2.4% | −13.1% |
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.